Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Recent declines on Wall Street have been unnerving for most investors. So far in the year the S&P 500 index has lost around 21%. But you can still find some interesting stocks to buy right now. Investing is a long-t...
10x Genomics Advances Leadership and Innovation in Single Cell and Spatial Technologies at 2022 AGBT General Meeting PR Newswire Demonstrates first-ever commercial product capable of single-cell RNA sequencing on FFPE tissues Opens preorders for CytAssist, th...
2022 has been brutal for early-stage biotech companies. Cathie Wood's Ark Genomic Revolution ETF is down 60% over the past year. Wood's long-term performance is outstanding, however, even after that huge drop. Some of her stocks have gotten a lot cheaper in the short term. But the poten...
Biotech is one of the fastest growing areas in healthcare, and one of the more exciting sectors in the stock market. Here's why three Fool.com contributors are bullish on 10x Genomics (NASDAQ: TXG) , Axsome Therapeutics (NASDAQ: AXSM) , and Doximity (NYSE: DOCS) ...
The release of Shockwave C² is a similar event to TAVRs for Edwards Lifesciences. Considering the cardiovascular industry tailwinds, the unique niche in calcified stenosis, and safety profile should allow a similar growth trajectory for SWAV. A tremendous earnings report...
10x Genomics (NASDAQ:TXG -8.1%) stock falls after the company on Wednesday posted wider Q1 net loss due to rise in costs. Net loss for the quarter was $42.4M as compared to a net loss of $11.6M, a year ago. GAAP EPS of -$0.38, missed estimates by $0.07. Revenue grew 8% Y/Y to $114....
10x Genomics, Inc. (TXG) Q1 2022 Earnings Conference Call May 04, 2022 04:30 PM ET Company Participants Cassie Corneau - Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer & Co-founder Justin McAnear - Chief Financial Officer Conference Call Participants Teja...
10x Genomics press release (NASDAQ:TXG): Q1 GAAP EPS of -$0.38 misses by $0.07. Revenue of $114.5M (+8.2% Y/Y) beats by $1.17M. 10x Genomics is maintaining its full year 2022 revenue guidance of $600 million to $630 million, representing 22% to 28% growth over full year 2021 revenue. For fu...
10x Genomics Reports First Quarter 2022 Financial Results PR Newswire Q1 2022 revenue growth of 8% over prior year PLEASANTON, Calif. , May 4, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first qua...
10x Genomics to Present at the BofA Securities 2022 Healthcare Conference PR Newswire PLEASANTON, Calif. , April 26, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...